Tuesday, January 13, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Is Workiva’s Recovery Gaining Momentum?

Dieter Jaworski by Dieter Jaworski
October 10, 2025
in Earnings, Nasdaq, Tech & Software, Turnaround
0
Workiva Stock
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

After navigating a challenging period in the markets, Workiva is demonstrating renewed vigor. The cloud-based software firm delivered an unexpectedly strong quarterly performance and subsequently upgraded its future outlook. This prompts a critical question for investors: is this upward trajectory sustainable following the significant decline witnessed earlier this year?

Strategic Shift Yields Tangible Results

A fundamental strategic realignment appears to be paying dividends for Workiva. The company is pivoting from a growth-at-all-costs model toward a more disciplined, profitable expansion. Management has notably raised its long-term EBIT margin target for 2027 from 16% to 18%, signaling confidence in a more mature and efficient business model.

This strategic focus is particularly evident in two areas. The Governance, Risk, and Compliance (GRC) division has emerged as a powerful growth engine, accelerating to a 30% annual growth rate. Furthermore, a concerted cross-selling initiative is proving highly successful, with multi-solution deal volume surging by an impressive 78%.

Quarterly Earnings Exceed Expectations

The second quarter of 2025 proved to be a standout period for Workiva. The company reported a substantial 21% year-over-year revenue increase to $215 million, comfortably surpassing analyst projections. Perhaps more importantly, this growth rate represents an acceleration from the preceding quarter.

Should investors sell immediately? Or is it worth buying Workiva?

Profitability metrics were equally compelling. Earnings per share came in at $0.19, dramatically outperforming the $0.05 consensus estimate. The company’s ability to deepen relationships with its existing client base was a key driver, reflected in a net revenue retention rate climbing to 114%—a multi-year high. Significant growth was also seen in the enterprise segment, with the number of large customers committing over $100,000 in contract value growing by up to 37%.

The AI Factor and Market Outlook

Workiva’s strategic rollout of its “Workiva AI” platform could be a potential game-changer. This initiative provides executives with tools to generate reports using pre-built templates and optimize workflows through an AI-powered assistant. The timing is opportune, as regulatory demands for complex ESG (Environmental, Social, and Governance) reporting continue to expand, affecting a growing number of corporations.

Despite the recent positive momentum, Workiva’s stock remains in negative territory for the year-to-date period. However, the analyst community is largely optimistic. Out of twelve market experts covering the firm, ten maintain a “Buy” recommendation. The consensus price target sits at $94.10, while a separate Discounted Cash Flow (DCF) analysis suggests a fair value of $105.76—implying a potential 17% upside from current levels.

The central debate for investors now revolves around whether Workiva has truly initiated a lasting turnaround after its difficult start to the year, or if this represents merely a temporary respite. The latest financial and operational data, however, provides a solid foundation for cautious optimism.

Ad

Workiva Stock: Buy or Sell?! New Workiva Analysis from January 13 delivers the answer:

The latest Workiva figures speak for themselves: Urgent action needed for Workiva investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 13.

Workiva: Buy or sell? Read more here...

Tags: Workiva
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Almonty Stock
Commodities

Almonty’s Strategic Pivot: From Defense to Fusion Energy

January 13, 2026
Novo Nordisk Stock
Earnings

Novo Nordisk Bets on Oral Wegovy to Expand Weight-Loss Market Reach

January 13, 2026
CureVac Stock
Mergers & Acquisitions

CureVac’s Stock Journey Concludes Following BioNTech Acquisition

January 13, 2026
Next Post
Clearside Biomedical Stock

Clearside Biomedical Secures Nasdaq Listing Compliance

IO Biotech Stock

Clinical Setback Sparks Drastic Overhaul at IO Biotech

IBM Stock

IBM's Strategic AI Partnership Fuels Market Optimism

Recommended

Blackbaud Stock

Blackbaud Emerges as Quiet Performer in Non-Profit Software Sector

5 months ago
Warner Bros. Discovery (A) Stock

Analysts Sound Caution on Warner Bros. Discovery Shares Despite Strong Performance

4 months ago
Summit Hotel Properties Stock

Summit Hotel Properties Maintains Dividend Amid Challenging Quarter

5 months ago
EOG stock news

SG Americas Securities LLC Strengthens Portfolio with Strategic Investment in Coastal Financial Co.

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

A Deep Dive into the iShares MSCI World ETF’s Performance and Strategy

Pfizer’s Strategic Shift Weighs on Investor Sentiment

Analyst Downgrade Overshadows PayPal’s Strategic Moves

Ethereum’s Quiet Consolidation Masks a Strengthening Foundation

Fiserv Embarks on Strategic AI Push Amid Leadership Reshuffle

Alphabet Reaches Historic Valuation Milestone on Dual Strategic Wins

Trending

Almonty Stock
Commodities

Almonty’s Strategic Pivot: From Defense to Fusion Energy

by Felix Baarz
January 13, 2026
0

Investor attention is turning toward Almonty Industries Inc. as the tungsten producer becomes linked to two powerful...

Novo Nordisk Stock

Novo Nordisk Bets on Oral Wegovy to Expand Weight-Loss Market Reach

January 13, 2026
CureVac Stock

CureVac’s Stock Journey Concludes Following BioNTech Acquisition

January 13, 2026
MSCI World ETF Stock

A Deep Dive into the iShares MSCI World ETF’s Performance and Strategy

January 13, 2026
Pfizer Stock

Pfizer’s Strategic Shift Weighs on Investor Sentiment

January 13, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Almonty’s Strategic Pivot: From Defense to Fusion Energy
  • Novo Nordisk Bets on Oral Wegovy to Expand Weight-Loss Market Reach
  • CureVac’s Stock Journey Concludes Following BioNTech Acquisition

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com